West Pharmaceutical price target lowered to $325 from $470 at KeyBanc

KeyBanc analyst Paul Knight lowered the firm’s price target on West Pharmaceutical (WST) to $325 from $470 to reflect lower FY25 estimates and confidence in long-term fundamentals, while keeping an Overweight rating on the shares. The firm notes West beat Q4 expectations, but the stock is down significantly due to disappointing FY25 guidance of 2%-3% organic growth vs. KeyBanc at +7.2% and the Street at 6.1%.